Aureus Pharma to Participate in a European Consortium for Drug Cardiac Toxicity
News Oct 31, 2008
Aureus Pharma has announced that they will participate in a consortium along with a number of industrial and academic research teams in a European Commission funded project entitled “preDiCT: Computational Prediction of Drug Cardiac Toxicity”.
The goal of the three year preDiCT project is to develop models to predict the effects of drugs on the heart. This is an important mission as many potential drug candidates fail during drug development due to adverse cardiotox safety factors. Computer models for cardiotoxicity will not only help to prioritize but also ultimately avoid costly laboratory experimentation.
Aureus’ contribution to the project will be to use its expertise in Ion Channel/hERG knowledge databases and knowledge management to design, build and populate the platform required for storing the experimental data that will be used to build models as well as the framework for collecting the knowledge generated in the modeling studies.
“We are delighted to participate in this important scientific initiative driven by a prestigious partner University Of Oxford in the United Kingdom,” commented Jason Theodosiou, CEO of Aureus Pharma.
“Our AurSCOPE Ion Channel and hERG knowledge databases and Aureus’ expertise in building knowledge management registration systems, provides a strong foundation to build upon for Aureus’ contributions to this project,” Theodosiou continued.
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE
'Body-on-a-Chip' Could Advance Drug EvaluationNews
MIT engineers have developed new technology that could be used to evaluate new drugs and detect possible side effects before the drugs are tested in humans. Using a microfluidic platform that connects engineered tissues from up to 10 organs, the researchers can accurately replicate human organ interactions for weeks at a time.READ MORE
Hope for Hot Flushes: New Class of Menopause Drugs Reduces SeverityNews
A new class of experimental drugs reduces hot flushes in menopausal women by almost three-quarters in just three days. The new analysis, published in the journal Menopause, also revealed sleep and concentration significantly improved in the three-day window.